DDO-6600
DDO-6600 is a covalent Hsp90 inhibitor. DDO-6600 disrupts the interaction between Hsp90 and its co-chaperone protein Cdc37, thereby inducing the degradation of kinase client proteins (such as AKT, CDK4, c-Raf) . DDO-6600 has inhibitory activity against various cancer cells. DDO-6600 inhibits the migration and invasion of HCT-116 cells, and induces cell cycle arrest and apoptosis. DDO-6600 significantly inhibits tumor growth in the HCT-116 xenograft tumor model. DDO-6600 can be used for research on colorectal cancer[1].
Product Specifications
CAS Number
2640292-37-9
UNSPSC
12352005
Target
Akt; Apoptosis; CDK; HSP; Raf
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR
Field of Research
Cancer
Smiles
O=C(N1C(CCCC1)C(N)=O)/C=C/C2=CN(C3=CC=CC=C3)N=C2C4=CC(C)=C(C=C4)C
Molecular Formula
C26H28N4O2
Molecular Weight
428.53
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Akt; CDK4; C-Raf; HSP90
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Carcinoembryonic Antigen (CEA) / CD66 (rC66/1009), CF405S conjugate, 0.1mg/mL
Alkaline Phosphatase (Placental) / PLAP (Germ Cell Tumor Marker) (ALPP/2899R), CF647 conjugate, 0.1mg/mL
C1QA / Complement C1q A-Chain (C1QA/2955), CF740 conjugate, 0.1mg/mL
Recombinant Human ERK2/MAPK1/MAPK2 Protein (GST Tag)
Topoisomerase I, Mitochondrial (TOP1MT) (TOP1MT/2883R), CF405S conjugate, 0.1mg/mL
